Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2013

Open Access 01-12-2013 | Research article

Addressing the contribution of previously described genetic and epidemiological risk factors associated with increased prostate cancer risk and aggressive disease within men from South Africa

Authors: Elizabeth A Tindall, MS Riana Bornman, Smit van Zyl, Alpheus M Segone, L Richard Monare, Philip A Venter, Vanessa M Hayes

Published in: BMC Urology | Issue 1/2013

Login to get access

Abstract

Background

Although African ancestry represents a significant risk factor for prostate cancer, few studies have investigated the significance of prostate cancer and relevance of previously defined genetic and epidemiological prostate cancer risk factors within Africa. We recently established the Southern African Prostate Cancer Study (SAPCS), a resource for epidemiological and genetic analysis of prostate cancer risk and outcomes in Black men from South Africa. Biased towards highly aggressive prostate cancer disease, this is the first reported data analysis.

Methods

The SAPCS is an ongoing population-based study of Black men with or without prostate cancer. Pilot analysis was performed for the first 837 participants, 522 cases and 315 controls. We investigate 46 pre-defined prostate cancer risk alleles and up to 24 epidemiological measures including demographic, lifestyle and environmental factors, for power to predict disease status and to drive on-going SAPCS recruitment, sampling procedures and research direction.

Results

Preliminary results suggest that no previously defined risk alleles significantly predict prostate cancer occurrence within the SAPCS. Furthermore, genetic risk profiles did not enhance the predictive power of prostate specific antigen (PSA) testing. Our study supports several lifestyle/environmental factors contributing to prostate cancer risk including a family history of cancer, diabetes, current sexual activity and erectile dysfunction, balding pattern, frequent aspirin usage and high PSA levels.

Conclusions

Despite a clear increased prostate cancer risk associated with an African ancestry, experimental data is lacking within Africa. This pilot study is therefore a significant contribution to the field. While genetic risk factors (largely European-defined) show no evidence for disease prediction in the SAPCS, several epidemiological factors were associated with prostate cancer status. We call for improved study power by building on the SAPCS resource, further validation of associated factors in independent African-based resources, and genome-wide approaches to define African-specific risk alleles.
Appendix
Available only for authorised users
Literature
1.
Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, et al: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009, 360 (13): 1310-1319. 10.1056/NEJMoa0810696.CrossRefPubMedPubMedCentral
2.
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009, 360 (13): 1320-1328. 10.1056/NEJMoa0810084.CrossRefPubMed
3.
Wever EM, Draisma G, Heijnsdijk EA, Roobol MJ, Boer R, Otto SJ, de Koning HJ: Prostate-specific antigen screening in the United States vs in the European randomized study of screening for prostate cancer-Rotterdam. J Natl Cancer Inst. 2010, 102 (5): 352-355. 10.1093/jnci/djp533.CrossRefPubMedPubMedCentral
4.
Hoffman RM: Clinical practice. Screening for prostate cancer. N Engl J Med. 2011, 365 (21): 2013-2019. 10.1056/NEJMcp1103642.CrossRefPubMed
5.
Lee GL, Dobi A, Srivastava S: Prostate cancer: diagnostic performance of the PCA3 urine test. Nat Rev Urol. 2011, 8 (3): 123-124. 10.1038/nrurol.2011.10.CrossRefPubMed
6.
Helfand BT, Kan D, Modi P, Catalona WJ: Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a “normal” prostate specific antigen and digital rectal examination. Prostate. 2011, 71 (4): 394-402. 10.1002/pros.21253.CrossRefPubMed
7.
Johansson M, Holmström B, Hinchliffe SR, Bergh A, Stenman UH, Hallmans G, Wiklund F, Stattin P: Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: longitudinal study. Int J Cancer. 2012, 130 (1): 129-137. 10.1002/ijc.25986.CrossRefPubMed
8.
Delongchamps NB, Singh A, Haas GP: Epidemiology of prostate cancer in Africa: another step in the understanding of the disease?. Curr Probl Cancer. 2007, 31 (3): 226-236. 10.1016/j.currproblcancer.2007.01.004.CrossRefPubMed
9.
Parkin DM, Sitas F, Chirenje M, Stein L, Abratt R, Wabinga H: Part I: Cancer in Indigenous Africans–burden, distribution, and trends. Lancet Oncol. 2008, 9 (7): 683-692. 10.1016/S1470-2045(08)70175-X.CrossRefPubMed
10.
Heyns CF, Fisher M, Lecuona A, van der Merwe A: Prostate cancer among different racial groups in the Western Cape: presenting features and management. S Afr Med J. 2011, 101 (4): 267-270.CrossRefPubMed
11.
Bigler SA, Pound CR, Zhou X: A retrospective study on pathologic features and racial disparities in prostate cancer. Prostate Cancer. 2011, 2011: 239460-CrossRefPubMedPubMedCentral
12.
Peters N, Armstrong K: Racial differences in prostate cancer treatment outcomes: a systematic review. Cancer Nurs. 2005, 28 (2): 108-118.CrossRefPubMed
13.
Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G: The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008, 15 (1): 3866-3871.PubMedPubMedCentral
14.
Reddy S, Shapiro M, Morton R, Brawley OW: Prostate cancer in black and white Americans. Cancer Metastasis Rev. 2003, 22 (1): 83-86. 10.1023/A:1022216119066.CrossRefPubMed
15.
Cheng I, Chen GK, Nakagawa H, He J, Wan P, Lurie C, Shen J, Sheng X, Pooler LC, Crenshaw AT, et al: Evaluating genetic risk for prostate cancer among Japanese and Latinos. Cancer Epidemiol Biomarkers Prev. 2012, 21 (11): 2048-2058. 10.1158/1055-9965.EPI-12-0598.CrossRefPubMedPubMedCentral
16.
Takata R, Akamatsu S, Kubo M, Takahashi A, Hosono N, Kawaguchi T, Tsunoda T, Inazawa J, Kamatani N, Ogawa O, et al: Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet. 2010, 42 (9): 751-754. 10.1038/ng.635.CrossRefPubMed
17.
Akamatsu S, Takata R, Haiman CA, Takahashi A, Inoue T, Kubo M, Furihata M, Kamatani N, Inazawa J, Chen GK, et al: Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. Nat Genet. 2012, 44 (4): 426-429. 10.1038/ng.1104. S421CrossRefPubMed
18.
Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, Rybicki BA, Isaacs WB, Ingles SA, Stanford JL, et al: Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet. 2011, 43 (6): 570-573. 10.1038/ng.839.CrossRefPubMedPubMedCentral
19.
Chung CC, Magalhaes WC, Gonzalez-Bosquet J, Chanock SJ: Genome-wide association studies in cancer–current and future directions. Carcinogenesis. 2010, 31 (1): 111-120. 10.1093/carcin/bgp273.CrossRefPubMed
20.
Lagiou A, Samoli E, Georgila C, Minaki P, Barbouni A, Tzonou A, Trichopoulos D, Lagiou P: Occupational physical activity in relation with prostate cancer and benign prostatic hyperplasia. Eur J Cancer Prev. 2008, 17 (4): 336-339. 10.1097/CEJ.0b013e3282f5221e.CrossRefPubMed
21.
Parent ME, Désy M, Siemiatycki J: Does exposure to agricultural chemicals increase the risk of prostate cancer among farmers?. Mcgill J Med. 2009, 12 (1): 70-77.PubMedPubMedCentral
22.
23.
Wright JL, Page ST, Lin DW, Stanford JL: Male pattern baldness and prostate cancer risk in a population-based case–control study. Cancer Epidemiol. 2010, 34 (2): 131-135. 10.1016/j.canep.2010.02.003.CrossRefPubMedPubMedCentral
24.
Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, Waliszewska A, Neubauer J, Tandon A, Schirmer C, McDonald GJ, et al: Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet. 2007, 39 (5): 638-644. 10.1038/ng2015.CrossRefPubMedPubMedCentral
25.
Storey JD, Tibshirani R: Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 2003, 100 (16): 9440-9445. 10.1073/pnas.1530509100.CrossRefPubMedPubMedCentral
26.
Benjamini Y, Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B (Methodological). 1995, 57 (1): 289-300.
27.
DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988, 44 (3): 837-845. 10.2307/2531595.CrossRefPubMed
28.
Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, Severi G, Leongamornlert DA, Tymrakiewicz M, Jhavar S, Saunders E, et al: Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet. 2009, 41 (10): 1058-1060. 10.1038/ng.452.CrossRefPubMed
29.
Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon A, Waliszewska A, Penney K, Steen RG, Ardlie K, John EM, et al: Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A. 2006, 103 (38): 14068-14073. 10.1073/pnas.0605832103.CrossRefPubMedPubMedCentral
30.
Coetzee GA: The usefulness of prostate cancer genome-wide association studies. J Urol. 2012, 187 (1): 9-10. 10.1016/j.juro.2011.10.057.CrossRefPubMed
31.
Schenk JM, Kristal AR, Arnold KB, Tangen CM, Neuhouser ML, Lin DW, White E, Thompson IM: Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. Am J Epidemiol. 2011, 173 (12): 1419-1428. 10.1093/aje/kwq493.CrossRefPubMedPubMedCentral
32.
McNeal JE, Redwine EA, Freiha FS, Stamey TA: Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol. 1988, 12 (12): 897-906. 10.1097/00000478-198812000-00001.CrossRefPubMed
33.
34.
FitzGerald LM, Kwon EM, Conomos MP, Kolb S, Holt SK, Levine D, Feng Z, Ostrander EA, Stanford JL: Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011, 20 (6): 1196-1203. 10.1158/1055-9965.EPI-10-1299.CrossRefPubMedPubMedCentral
35.
Nam RK, Zhang W, Siminovitch K, Shlien A, Kattan MW, Klotz LH, Trachtenberg J, Lu Y, Zhang J, Yu C, et al: New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohort. Cancer Biol Ther. 2011, 12 (11): 997-1004. 10.4161/cbt.12.11.18366.CrossRefPubMedPubMedCentral
36.
Elshafei A, Moussa AS, Hatem A, Ethan V, Panumatrassamee K, Hernandez AV, Jones JS: Does positive family history of prostate cancer increase the risk of prostate cancer on initial prostate biopsy?. Urology. 2013, 81 (4): 826-830. 10.1016/j.urology.2012.10.074.CrossRefPubMed
37.
Thomas JA, Gerber L, Bañez LL, Moreira DM, Rittmaster RS, Andriole GL, Freedland SJ: Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev. 2012, 21 (4): 576-581. 10.1158/1055-9965.EPI-11-1017.CrossRefPubMed
38.
Giles GG, Severi G, Sinclair R, English DR, McCredie MR, Johnson W, Boyle P, Hopper JL: Androgenetic alopecia and prostate cancer: findings from an Australian case–control study. Cancer Epidemiol Biomarkers Prev. 2002, 11 (6): 549-553.PubMed
39.
Nicolucci A: Epidemiological aspects of neoplasms in diabetes. Acta Diabetol. 2010, 47 (2): 87-95. 10.1007/s00592-010-0187-3.CrossRefPubMed
40.
Fall K, Garmo H, Gudbjörnsdottir S, Stattin P, Zethelius B: Diabetes mellitus and prostate cancer risk; a nationwide case–control study within PCBaSe Sweden. Cancer Epidemiol Biomarkers Prev. 2013, 22 (6): 1102-1109. 10.1158/1055-9965.EPI-12-1046.CrossRefPubMed
41.
Lawrence YR, Morag O, Benderly M, Boyko V, Novikov I, Dicker AP, Goldbourt U, Behar S, Barchana M, Wolf I: Association between metabolic syndrome, diabetes mellitus and prostate cancer risk. Prostate Cancer Prostatic Dis. 2013, 16 (2): 181-186. 10.1038/pcan.2012.54.PubMed
42.
Snyder CF, Stein KB, Barone BB, Peairs KS, Yeh HC, Derr RL, Wolff AC, Carducci MA, Brancati FL: Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate Cancer Prostatic Dis. 2010, 13 (1): 58-64. 10.1038/pcan.2009.39.CrossRefPubMed
43.
Gunter JH, Sarkar PL, Lubik AA, Nelson CC: New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication. Int J Cell Biol. 2013, 2013: 834684-CrossRefPubMedPubMedCentral
44.
Giles GG, Severi G, English DR, Hopper JL: Frequency of ejaculation and risk of prostate cancer. JAMA. 2004, 292 (3): 329-author reply 329PubMed
45.
Veitonmäki T, Tammela TL, Auvinen A, Murtola TJ: Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer. 2013, 49 (4): 938-945. 10.1016/j.ejca.2012.09.030.CrossRefPubMed
46.
Van Dyk JC, Bouwman H, Barnhoorn IE, Bornman MS: DDT contamination from indoor residual spraying for malaria control. Sci Total Environ. 2010, 408 (13): 2745-2752. 10.1016/j.scitotenv.2010.03.002.CrossRefPubMed
47.
Bornman R, de Jager C, Worku Z, Farias P, Reif S: DDT and urogenital malformations in newborn boys in a malarial area. BJU Int. 2010, 106 (3): 405-411. 10.1111/j.1464-410X.2009.09003.x.CrossRefPubMed
48.
DeGiorgio M, Jakobsson M, Rosenberg NA: Out of Africa: modern human origins special feature: explaining worldwide patterns of human genetic variation using a coalescent-based serial founder model of migration outward from Africa. Proc Natl Acad Sci U S A. 2009, 106 (38): 16057-16062. 10.1073/pnas.0903341106.CrossRefPubMedPubMedCentral
Metadata
Title
Addressing the contribution of previously described genetic and epidemiological risk factors associated with increased prostate cancer risk and aggressive disease within men from South Africa
Authors
Elizabeth A Tindall
MS Riana Bornman
Smit van Zyl
Alpheus M Segone
L Richard Monare
Philip A Venter
Vanessa M Hayes
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2013
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/1471-2490-13-74

Other articles of this Issue 1/2013

BMC Urology 1/2013 Go to the issue

Research article

Prognostic benefit of surgical management in renal cell carcinoma patients with thrombus extending to the renal vein and inferior vena cava: 17-year experience at a single center

Case report

Therapy-resistant nephrolithiasis following renal artery coil embolization

Research article

Treatment patterns and characteristics of European patients with castration-resistant prostate cancer

Case report

Sequential bilateral testicular tumours presenting with intervals of 20 years and more

Research article

Neuromodulation attenuates bladder hyperactivity in a rat cystitis model

Research article

Elevated C-reactive protein values predict nodal metastasis in patients with penile cancer